Journal of Clinical Endocrinology & Metabolism, Vol 54, 1113-1117, Copyright © 1982 by Endocrine Society

ARTICLES

High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel

MJ Tikkanen, EA Nikkila, T Kuusi and SU Sipinen

The concentrations of plasma high density lipoprotein (HDL) and its subfraction HDL2 are influenced by endogenous and exogenous sex hormones. The catabolism of HDL2 is mediated by a lipolytic enzyme, hepatic lipase, which is present in endothelial cells covering the liver sinusoids. Since the activity of this enzyme is also regulated by gonadal and anabolic steroids, we examined whether the effect of sex steroids on plasma HDL is related to changes in hepatic lipase. In postmenopausal women, estradiol valerate (2 mg/day, orally) increased the HDL2 cholesterol and phospholipid concentrations by 20% (P less than 0.05). Simultaneously, the hepatic lipase activity of postheparin plasma decreased by 25% (P less than 0.05). The addition of levonorgestrel (250 micrograms/day, orally) to the treatment reversed both effects of estrogen, so that HDL2 cholesterol and phospholipid levels fell below and hepatic lipase activity rose above the respective pretreatment values. The hormones did not influence the HDL3 lipid concentrations or the lipoprotein lipase and lecithin:cholesterol acyltransferase activities. The results are compatible with the hypothesis that the effects of sex steroids on plasma HDL (HDL2) are mediated by changes in hepatic lipase activity.

This article has been cited by other articles:

				F. Magkos, B. W. Patterson, and B. Mittendorfer No effect of menstrual cycle phase on basal very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1243 - E1249. [Abstract] [Full Text] [PDF]

				M. C. Carr, R. H. Knopp, J. D. Brunzell, B. S. Wheeler, X. Zhu, M. Lakshmanan, A. S. Rosen, and P. W. Anderson Effect of Raloxifene on Serum Triglycerides in Women With a History of Hypertriglyceridemia While on Oral Estrogen Therapy Diabetes Care, July 1, 2005; 28(7): 1555 - 1561. [Abstract] [Full Text] [PDF]

				J. W. Burgess, T. A-M. Neville, P. Rouillard, Z. Harder, D. S. Beanlands, and D. L. Sparks Phosphatidylinositol increases HDL-C levels in humans J. Lipid Res., February 1, 2005; 46(2): 350 - 355. [Abstract] [Full Text] [PDF]

				A.-S. Furberg, G. Jasienska, N. Bjurstam, P. A. Torjesen, A. Emaus, S. F. Lipson, P. T. Ellison, and I. Thune Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. The Norwegian EBBA Study Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 33 - 40. [Abstract] [Full Text] [PDF]

				A.-S. Furberg, M. B. Veierod, T. Wilsgaard, L. Bernstein, and I. Thune Serum High-Density Lipoprotein Cholesterol, Metabolic Profile, and Breast Cancer Risk J Natl Cancer Inst, August 4, 2004; 96(15): 1152 - 1160. [Abstract] [Full Text] [PDF]

				M. Muller, Y. T. van der Schouw, J. H. H. Thijssen, and D. E. Grobbee Endogenous Sex Hormones and Cardiovascular Disease in Men J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5076 - 5086. [Abstract] [Full Text] [PDF]

				E. Barrett-Connor An Epidemiologist Looks at Hormones and Heart Disease in Women J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4031 - 4042. [Full Text] [PDF]

				S. S. Deeb, A. Zambon, M. C. Carr, A. F. Ayyobi, and J. D. Brunzell Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet J. Lipid Res., July 1, 2003; 44(7): 1279 - 1286. [Abstract] [Full Text] [PDF]

				Y. Somekawa, H. Umeki, K. Kobayashi, S. Tomura, T. Aso, and H. Hamaguchi Effects of Hormone Replacement Therapy and Hepatic Lipase Polymorphism on Serum Lipid Profiles in Postmenopausal Japanese Women J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4766 - 4770. [Abstract] [Full Text] [PDF]

				B. Perret, L. Mabile, L. Martinez, F. Terce, R. Barbaras, and X. Collet Hepatic lipase: structure/function relationship, synthesis, and regulation J. Lipid Res., August 1, 2002; 43(8): 1163 - 1169. [Abstract] [Full Text] [PDF]

				R. M. Krauss Individualized Hormone-Replacement Therapy? N. Engl. J. Med., March 28, 2002; 346(13): 1017 - 1018. [Full Text] [PDF]

				M. C. Carr, J. E. Hokanson, A. Zambon, S. S. Deeb, P. H. R. Barrett, J. Q. Purnell, and J. D. Brunzell The Contribution of Intraabdominal Fat to Gender Differences in Hepatic Lipase Activity and Low/High Density Lipoprotein Heterogeneity J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2831 - 2837. [Abstract] [Full Text] [PDF]

				E. EDMUNDS and G.Y.H. LIP Cardiovascular risk in women: the cardiologist's perspective QJM, March 1, 2000; 93(3): 135 - 145. [Full Text] [PDF]

				N. Enomoto, S. Yamashina, P. Schemmer, C. A. Rivera, B. U. Bradford, A. Enomoto, D. A. Brenner, and R. G. Thurman Estriol sensitizes rat Kupffer cells via gut-derived endotoxin Am J Physiol Gastrointest Liver Physiol, September 1, 1999; 277(3): G671 - G677. [Abstract] [Full Text] [PDF]

				S. L. Crawford and C. B. Johannes The Epidemiology of Cardiovascular Disease in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1803 - 1806. [Full Text]

				F. C. W. Wu, R. Balasubramanian, T. M. T. Mulders, and H. J. T. Coelingh-Bennink Oral Progestogen Combined with Testosterone as a Potential Male Contraceptive: Additive Effects between Desogestrel and Testosterone Enanthate in Suppression of Spermatogenesis, Pituitary-Testicular Axis, and Lipid Metabolism J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 112 - 122. [Abstract] [Full Text]

				F.-Y. Jin, V. S. Kamanna, and M. L. Kashyap Estradiol Stimulates Apolipoprotein A-I– but Not A-II–Containing Particle Synthesis and Secretion by Stimulating mRNA Transcription Rate in Hep G2 Cells Arterioscler. Thromb. Vasc. Biol., June 1, 1998; 18(6): 999 - 1006. [Abstract] [Full Text] [PDF]

				W.-C. Song, Y. Qian, and A. P. Li Estrogen Sulfotransferase Expression in the Human Liver: Marked Interindividual Variation and Lack of Gender Specificity J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1197 - 1202. [Abstract] [Full Text]

				F. Tato, G. L. Vega, and S. M. Grundy Determinants of Plasma HDL-Cholesterol in Hypertriglyceridemic Patients: Role of Cholesterol-Ester Transfer Protein and Lecithin Cholesteryl Acyl Transferase Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 56 - 63. [Abstract] [Full Text]

				V. Guetta and R. O. Cannon III Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women Circulation, May 15, 1996; 93(10): 1928 - 1937. [Full Text]

				M. Miller, R. G. Burgan, L. Osterlund, J. P. Segrest, and D. W. Garber A Prospective, Randomized Trial of Phenytoin in Nonepileptic Subjects With Reduced HDL Cholesterol Arterioscler. Thromb. Vasc. Biol., December 1, 1995; 15(12): 2151 - 2156. [Abstract] [Full Text]

				A. A. Nabulsi, A. R. Folsom, A. White, W. Patsch, G. Heiss, K. K. Wu, M. Szklo, and The Atherosclerosis Risk in Communities Study Inve Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women N. Engl. J. Med., April 15, 1993; 328(15): 1069 - 1075. [Abstract] [Full Text]